Detalhe da pesquisa
1.
Patient-centered outcomes in the POLO study of active maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.
Cancer
; 129(9): 1411-1418, 2023 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36811344
2.
Real-world outcomes for first line next-generation hormonal agents in metastatic prostate cancer: a systematic review.
Future Oncol
; 19(36): 2425-2443, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37681288
3.
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial.
Lancet Oncol
; 22(5): 632-642, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33862001
4.
Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States.
Gynecol Oncol
; 159(2): 491-497, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32951894
5.
Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study.
Value Health
; 22(7): 772-776, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31277823
6.
A matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia.
Am J Hematol
; 98(12): E387-E390, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37811799
7.
Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
BMC Health Serv Res
; 17(1): 182, 2017 03 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28270207
8.
Cost-Effectiveness Analysis of Adjuvant Olaparib Versus Watch and Wait in the Treatment of Germline BRCA1/2-Mutated, High-Risk, HER2-Negative Early Breast Cancer in Sweden.
Pharmacoecon Open
; 8(2): 277-289, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38093030
9.
Survival Extrapolation Incorporating General Population Mortality Using Excess Hazard and Cure Models: A Tutorial.
Med Decis Making
; 43(6): 737-748, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37448102
10.
Association between event-free survival and overall survival after neoadjuvant treatment for non-small cell lung cancer: a systematic review and meta-analysis.
Expert Rev Anticancer Ther
; 23(12): 1305-1313, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37850939
11.
Indirect treatment comparison of olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer.
J Comp Eff Res
; 10(13): 1021-1030, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34231369
12.
Real-world treatment patterns and outcomes in small-cell lung cancer: a systematic literature review.
J Thorac Dis
; 13(6): 3692-3707, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34277061
13.
Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer.
Ther Adv Med Oncol
; 13: 17588359211049639, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34616492
14.
Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore.
J Gynecol Oncol
; 32(2): e27, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33559410
15.
Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Target Oncol
; 16(5): 613-623, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34478046
16.
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
Eur J Cancer
; 157: 415-423, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34597975
17.
Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods.
Adv Ther
; 37(1): 225-239, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31701485
18.
A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.
Pharmacoeconomics
; 38(11): 1201-1218, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32794041
19.
Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.
Eur J Cancer
; 120: 20-30, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31446213
20.
Author response to 'Comment on "Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer" (Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639)'.
Ther Adv Med Oncol
; 15: 17588359231168519, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37113736